Icon
+91 94997 68112
Login Register

Ofev - (100, 150 mg; Capsule, Oral)

Nintedanib Boehringer Ingelheim
100, 150 mg; Capsule, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
Ofev is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Ofev is indicated for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype
Yes
* **** ** ***** ** * ******* *********, *** *** ******* ** ********* *** *******. ** *** **, **** ****** ******** * ********* ******** **** *** *** ********** ******** ***** *** *****. ******** **** ******** * ********* ******** ** *** **, ****. ** *** ** **** **** *** ******** ****** ** *** ********** ********* **** * ****-*** *** **** ***** ** *** ******** ******* **** ** ****** ****** ** *** *, ****. **** ********* **** ***** * ****-** ** *** ******* '*** *** '***. ** *** **** ********* **** ** ********** *** ********* ******* ****** ****** ** ******** ** *** *** ****** (**********) . ** *** *, **** ***** ***** * ****** ********* ******* **********. ** *** ******* * *********** ********* ** ***-************ ** *** ******* ** ***** ** *** ***** * ****-** ('*** & '***). ** ****** ** ***** * **** *** ** '*** *** '***. ** *** **, **** ***** ******** * ********* ******** *** ********** ******** . ** ********** *********** ** ********* *** *** ****. ** *** **, **** ***** ******** * ********* ******** *** ********** ******** . ** ********** *********** ** ********* *** *** ****.
Ofev Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
****** (*****) **** *** **** *** *** ********* *** ********* ****** ***
******** **** *** **** *** *** ********* *** ********* ****** ***
***** **** *** **** *** ******* ******* **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** (*****) *** \ ********* -**- *** ********* ********* ******** ** *** *, ****
******** *** \ ********* -**- *** ********* ********* ******** ** *** *, ****
***** *** \ ********* -**- ******* **** ** *** *, ****
  1. *** **, **** : * ****-** ** ***** *** ***** *** * *** *********. ****** *** ******** **** ***** ** ** * ** *** ****. *** ***** * *** ********* ****** *******.
  2. *** **, **** : ******** ******** ********* ******** *** ********** ********. *** '*** ****** *** ***** ** ** ****** ***.
  3. *** *, **** : ****** ******** ********* ******** *** ********** ********. *** '*** ****** *** ***** ** ** ****** ***.
  4. *** *, **** : ***** ***** * **** ******* ********** ******* * *********** ********* ** ***-************ ** ******* '*** *** '***
  5. *** **, **** : ***** ******** * ********* ******** *** ********** ******** . ** ********** *********** ** ********* *** *** ****.
  6. *** **, **** : * ******** ******* ********* *** ********** ******* ***** *** ********** ** *****.
  7. *** **, **** : ********** ******* ***** *** ********** ** ******* *****. *****'* **** ***** ** ** ***-**********
  8. *** **, **** : ***** ******** * ********* ******** *** ********** ******** . ** ********** *********** ** ********* *** *** ****.
  9. *** **, **** : ****** **** ********** ******* * *********** ********* ** ***-************ ** ******* '*** *** '***. ** ****** **** **** *** ************, **** ****** *** ****** *** ******* **** *** ********.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.